{"name":"PolTREG S.A.","slug":"poltreg-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPOGt1YXRSbU1QM1RMcnZIM0VheWV0enNVbkJZT25TMlBkTjM4TF84ZUdfSjg4ZllhTWJ6bzJycXhxWF8ySkJVYVdoLV9UX1FQRmRCTzN4TUl0Ml9veHRHVmtzXy1udjY3dmRDaHZDMklTVTFoR0g5bk9URXFLV2xHejVXcTRHQjVGeTBKUUZ3QWNvd05ab1J0NlpQVEFfWkhSOXRWbkZYR2gxWThWUURNSThFTG54bmtzNnAxbVV3Q01KSVIxUjJ6TVRmWlZiUEJSbkVDalN2VjlDUUg4V3pITFVUa0haYWdBMUwyamY2bmV2ZEpQTG5vel9fR0w?oc=5","date":"2026-03-10","type":"pipeline","source":"GlobeNewswire","summary":"PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes - GlobeNewswire","headline":"PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWdGRTVzOWhMVlJyUkU3eXc2SjFDbl9lbm93VmphbEtwRXBybklIbjB1Njhvdk5KaXdDNkRURXdWaTlySWxaaUFuZVFjZlZPYVR4cWRNRkpzeUlKRjJsYVlUX0pIdWpsTkJRWlJLNm85ZHFZZG9ndHlSRy1xQXFNb3RWX0lpME9SOEJ1VFNCVzREWTA?oc=5","date":"2025-12-17","type":"pipeline","source":"Insightace Analytic","summary":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNZ2x1bTQyeHZKMVc2Y0tKOXVBaVhEbWxRYUVkMmVNU0ZGZnNOUkMxbllqUk5ZYW1LVHVJaURnckEtYTZrY3AtX0Vra1E3dEN5UE5QbV9NdXgyaVlJQ1BfeXhiMkxLT3RzQUMwV1pqQmxXZjFNVmVpYVBnV1N2TFo3WHI0V3dqTFh6SVVZZTA5NnFCS3YyRno2RmVwVUVwMXdLc19vWVNSa0dZbVg0M25ZZlFGQ0tvZC1yMlR0UW9pY2dvYTQybmhqN2pJS2ozNkU?oc=5","date":"2025-08-04","type":"trial","source":"BioSpace","summary":"PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 - BioSpace","headline":"PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxPRVhnWlpBZFFJNWZ5dnBkM2FCbTAyNXJmdDBBSWF4LTFZTmhBblh1V1FROGNiVEpWcy00STItalFEN190ck0zd2JoNXIxeklpQ1Z3QWwySnhCaWVjRlctU2UzZDB1YTNUc3F0dldoT2tLSUNJVGEtelpob3JnRzNSWVZBY3pYNHBXcmpPSHFQVS02VXZQVkNSZXRRMFprN040YTlyQWc2bS0xcnl1Q01SSmVCdmN1QjFEOWxFYmRiVGZRZFBqbmpXOExyWHBtTUMyNkVETHF1SDR0ODZpcUx6WlQ4a1hfdDRBbWdEU3pKbl9yME53RkZ6b2FnVFBJQUxkWFpYLUticFVQQQ?oc=5","date":"2025-08-01","type":"regulatory","source":"BioSpace","summary":"PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial - BioSpace","headline":"PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNV2ZubGxzdXhGR0pNRmhSZDlMaHVDMUdGNFp1X1lFZHRaM3FZNGxKNG5XZ09GeWx1Sjc5b25sdVR3S2czNy1MU2trZy1nX2ZzM1lubExUX3FzZFJaNHlQMDdQa2VxS1djaFMtUGFYQjA1cW9iUXJ1YnIwenRHdXZxRHkyV1FIbHh4Mml2RFowVS1WRlpHZXBKOWVXNEdRSnVPanBhQVlSNHlldVd4Yk45WXd4ZVZwSmdLaWw2R3ZRSXBkNzVFb1I4LTdR?oc=5","date":"2025-06-16","type":"pipeline","source":"BioSpace","summary":"PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy - BioSpace","headline":"PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdzFsb1ZfUDhodkp3ZUUwZDNaU0tKSUV0cVk5U0EtOGtQcDdDTkZHUmlncW1pSmtjc0Z3YmhhVUw3VUZXVDRlUDU1M2VSWFBRd0FQQmZuZ29MLUt5alZsbWJXTGxLQTBYbURxNVVfcXBBemQzWmhFcWpEOTV2a05xa0hhbXc0cmIxS0ZrcUwzUzB1bEVRVklZTGF5aUJnZ3FGc2VyVEduaHdGUm85QzljRlZ5NmdteXNaZkl5MTVDcV8tZTRSQlRVNldDemhIU0V6OEhz?oc=5","date":"2025-05-15","type":"regulatory","source":"BioSpace","summary":"Positive EMA Opinion on Pediatric Investigation Plan for PolTREG’s Treg Therapy in Type 1 Diabetes - BioSpace","headline":"Positive EMA Opinion on Pediatric Investigation Plan for PolTREG’s Treg Therapy in Type 1 Diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxONGl0M2pkNFg2SFZMdEFnS0Y1LVRkY3AtNXBpYUtLWkR6WXNOWUl3MlpEeHBZOV9jcUlnWVRscVpDWkJ0OHAxRlFYNGxiRU5mWGNaTS1GWEZJUjJoMG9ZQjlyUVBBYW10WUgzRUJ4eWtVcjk0ZHJzNnlqRGU0VVhzci1sQ0ZYRE16Qjk3N3dCZ1prWVNtUE5XYWROMTBieUxYR3JxUkk1Tlg4N3kzX2Z4LTY5RkhDZUpHX09TTmsyTGlqN0lQN0Iwck1pMXRXS2ctSkJDRE11VExQWm1zcjVTZXlEano4VEpHd1FCRTlrSG5Wbjd1Sk9Ma2k1dGtXQ3kwM1ktejBuc0hOaU5tX2l3TG9ydFhfYXQ4NnN1WGtocGlvcEp6bWZpOEJCc3FfTTVyY3c?oc=5","date":"2024-10-28","type":"trial","source":"PR Newswire","summary":"Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key Pharma Companies Actively Working in the T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRXFZX25Ud3JlQmw3SU05M0hnUDhUTWRucmUxV3RyRTFpN3VTNnRxTkRfQURjTk5xRmRGUnhOYUdKYlRUOUJYVm9UdVBiNXVlLTJ6RV9JcG5PQmpna3ZxN0lUZ21ZVGxTYlZIMGdfMnVGWGRhV1lsSl9BaFY0blM0MFhlUlhjUW5Jblk4?oc=5","date":"2024-03-11","type":"pipeline","source":"Manufacturing Chemist","summary":"PolTREG receives CGMP certification to produce cell therapies - Manufacturing Chemist","headline":"PolTREG receives CGMP certification to produce cell therapies","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}